Results 51 to 60 of about 21,501 (259)
JEADV Clinical Practice, Volume 5, Issue 2, Page 669-672, June 2026.ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge +5 more
wiley +1 more source
Erythema multiforme-like eruption from a slimming drug preparation cutaneous adverse drug reaction
Indian Dermatology Online Journal, 2011 We report a case of a 34-year-old woman presenting with an erythema multiforme (EM)-like eruption. Lesions developed after a 12-day treatment with a slimming drug preparation (food integrator with thermogenic activity) and a herbal remedy (pilosella ...
Linda Tognetti +2 more
doaj +1 more source
Granulomatous Panniculitis in a Patient Treated With Cemiplimab: Case Report and Literature Review
JEADV Clinical Practice, Volume 5, Issue 2, Page 664-668, June 2026.ABSTRACT Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced malignancies by enhancing antitumor immunity, but they may also trigger a broad spectrum of immune‐related adverse events (irAEs) involving multiple organs.
B. Lada‐Colunga +6 more
wiley +1 more source
Tenofovir induced lichenoid drug eruption
Avicenna Journal of Medicine, 2015 Cutaneous adverse reactions are a common complication of anti-retroviral therapy. Tenofovir is a newer anti-retroviral drug belonging to the nucleotide reverse transcriptase inhibitor group.
Mrinal Gupta, Heena Gupta, Anish Gupta
doaj +1 more source
JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series
JEADV Clinical Practice, EarlyView.ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni +6 more
wiley +1 more source
Case Reports in Dermatology, 2013 The introduction of ribavirin to hepatitis C combination therapy with pegylated interferon (PEG-IFN)-α2a has improved sustained responses, but it has been accompanied by an increased incidence of cutaneous side effects. Most cases of drug eruption caused
Masahisa Shindo, Isamu Terai
doaj +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Objectives Patients with SMX receiving high‐dose intravenous IVIg therapy were included to assess validity of the double modified ...
Julia K. Winkler, Alexander H. Enk
wiley +1 more source
Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective
JEADV Clinical Practice, Volume 5, Issue 2, Page 402-414, June 2026.Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek +3 more
wiley +1 more source
Refractory Eczema as a Presenting Feature of Common Variable Immunodeficiency
JEADV Clinical Practice, EarlyView.ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic inborn error of immunity (IEI) in adults. It presents with recurrent infections and non‐infectious complications, including autoimmunity, lymphoproliferation and dermatitis.
Mercedes Sanchez‐Diaz +2 more
wiley +1 more source